Early data on patients treated in Cohort C of the ALLOHA™ Phase 1 heme trial expected in the second quarter of 2026 ...
GAITHERSBURG, Md., US, 6 May 2026) Immunocore Holdings plc (Nasdaq: IMCR) ("Immunocore” or the "Company”), a commercial-stage biotechnology company pioneering and delivering transformative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results